PROTEA-PFO OUSNCT07698951
Evaluating Percutaneous Repair Of The Atrial Septum With A Novel PFO Occluder: The PROTEA-PFO OUS Study
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria expanded, about 10 words Show 5 more changesShow less
- Study completion pushed from Dec 2029 to Feb 2030
- Study sites: 1 to 2
- Primary completion date: Jul 2027 to Aug 2027
- Secondary endpoints: details revised at 1 of 2 entries
- Collaborators: details revised at 1 of 1 entry
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Effective PFO Closure
Timeframe: 6 months
Adverse Cardiovascular Events
Timeframe: 30 days
Secondary (2)
Rate of device-related or procedure-related Serious Adverse Events (SAEs)
Correct device position
Arms and interventions
Recross P3 Occluder (P3O) SystemExperimental
The Recross P3 Occluder (P3O) is being developed for the purpose of transcatheter closure of a patent foramen ovale (PFO) to reduce the risk of recurrent ischemic stroke in patients with PFO-associated stroke.
Devices: Recross P3 Occluder (P3O) System
Sites
2 sites in 1 country